CURE CONNECT

FROM PATIENTS
TO ADVANCED THERAPEUTICS

National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

Focus Your Search
(all filters optional)

<< Hide

Condition/disease

Non-small Cell Lung Cancer

Other terms

Intervention/treatment

Location

Search by address, city, state, or country and select from the dropdown list

Study Status

Looking for participants

- [ ] Not yet recruiting (331)
- [ ] Recruiting (1,315)

Focus Your Search
(all filters optional)

<< Hide

Condition/disease

Non-small Cell Lung Cancer

Other terms

Intervention/treatment

Location

Search by address, city, state, or country and select from the dropdown list

Philadelphia, PA

Study Status

Looking for participants

- [ ] Not yet recruiting (1)
- [ ] Recruiting (75)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

Description

3.1 Inclusion Criteria: - Eligibility Criteria

3.1.1 Age >/= 18 years

3.1.2 ECOG performance status 0-1 3.1.3 Histologically proven diagnosis of a prior thoracic malignancy treated with thoracic external beam radiotherapy with or without systemic chemotherapy

3.1.4 Pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy. A reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, CT guided lung biopsy)

- Loco-regional is defined as recurrence within the region of the primary tumor or adjacent draining lymph node regions.
- The new lesion or loco-regional recurrence must be within or adjacent to the previously irradiated treatment volume.

3.1.5 Imaging as follows:

- CT scan of the chest with IV contrast within 8 weeks of registration
- Whole body PET scan within 8 weeks of registration

3.1.6 Pulmonary function test (PFTs), including diffusion capacity within 8 weeks of registration

3.1.7 Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.

3.1.6 Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control

3.1.7 Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria:

- 3.2 Exclusion Criteria

3.2.1. No previously reported thoracic radiotherapy

3.2.2. FEV1 <20% predicted and/or DLCO <20% predicted

3.2.2. Pregnant women or lactating women

3.2.3 Chemotherapy within 4 weeks of the initiation of SABR

3.2.4 Plans to administer systemic chemotherapy overlapping with radiotherapy

– Show less

Ages Eligible for Study

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Who are the people that may be benefited from getting access to clinical trials?

- Patients with Chronic or Life-Threatening Illnesses
  - Over 1.9 million people diagnosed annually with cancer
  - 82 million people live with some form of heart disease
  - 37 million people have diabetes
  - 6 million people are living with Alzheimer's



User Demo

Our Pipeline



"Inclusion Criteria:\n\n1. The subject is at least 18 years old and\\<75 years old on the day of signing the informed consent form, regardless of gender, and is willing to follow the research procedure;\n2. Confirmed by histology or cytology as non-small cell lung cancer;\n3. NSCLC patients evaluated by researchers as resectable in stage IB-IIIB (stage IIIB only limited to T3N2M0) (AJCC 8th edition);\n4. Has not received any anti-tumor treatment in the past, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy;\n5. No allergenic EGFR mutation or ALK change;\n6. The ECOG score is 0-1 points. \n\nExclusion Criteria:\n\n1. The lesion of squamous non-small cell lung cancer presents as a central type of lung cancer accompanied by cavity formation or invasion of blood vessels, with a high risk of hemoptysis; \n2. Previously or currently suffering from interstitial pneumonia/lung disease that requires systemic hormone therapy;\n3. Previous history of allogeneic bone marrow or organ transplantation;\n4. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial;\n5. Prior to allocation, they have received systemic anti-cancer treatment, including research drugs targeting current malignant tumors;\n6. Other known malignant tumors are progressing or require active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding bladder carcinoma in situ) who have received possible radical treatment are not excluded;\n7. Pregnant and/or lactating women.'"

gpt4o


```
{
"Inclusion Criteria": {
  "Age": {
    "min": 18,
    "max": 75
  },
  "Diagnosis": "Non-small cell lung cancer",
  "Disease Stage": "IB-IIIB",
  "Resectability": true,
  "Previous Treatment": "None",
  "Genetic Mutations": {
    "EGFR": false,
    "ALK": false
  },
  "ECOG Score": {
    "min": 0,
    "max": 1
  }
},
"Exclusion Criteria": {
  "Lesion Type": "Squamous non-small cell lung cancer with central loca
tion and high risk of hemoptysis",
  "Interstitial Pneumonia/Lung Disease": "Systemic hormone therapy requ
ired",
  "Bone Marrow/Organ Transplantation": true,
  "Major Surgical Treatment": {
    "withinDays": 28
  },
  "Previous Anti-Cancer Treatment": true,
  "Other Malignant Tumors": {
    "Progression": true,
    "TreatmentRequiredWithinYears": 5
  },
  "Skin Cancers": {
    "Basal Cell Carcinoma": true,
    "Squamous Cell Carcinoma": true,
    "Carcinoma in situ (excluding bladder)": true
  },
  "Pregnancy or Lactation": true
}
```

"Inclusion Criteria:\n\n1. The subject is at least 18 years old and\\<75 years old on the day of signing the informed consent form, regardless of gender, and is willing to follow the research procedure;\n2. Confirmed by histology or cytology as non-small cell lung cancer;\n3. NSCLC patients evaluated by researchers as resectable in stage IB-IIIB (stage IIIB only limited to T3N2M0) (AJCC 8th edition);\n4. Has not received any anti-tumor treatment in the past, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy;\n5. No allergenic EGFR mutation or ALK change;\n6. The ECOG score is 0-1 points. \n\nExclusion Criteria:\n\n1. The lesion of squamous non-small cell lung cancer presents as a central type of lung cancer accompanied by cavity formation or invasion of blood vessels, with a high risk of hemoptysis; \n2. Previously or currently suffering from interstitial pneumonia/lung disease that requires systemic hormone therapy;\n3. Previous history of allogeneic bone marrow or organ transplantation;\n4. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial;\n5. Prior to allocation, they have received systemic anti-cancer treatment, including research drugs targeting current malignant tumors;\n6. Other known malignant tumors are progressing or require active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding bladder carcinoma in situ) who have received possible radical treatment are not excluded;\n7. Pregnant and/or lactating women.'"

- **Structured output** via schema defined in Pydantic
- **Parameter** tuning

gpt4o-20
24-08-06

```json
{
    "age": ((18, 75), "tuple(int)", "years", True),
    "non_small_cell_lung_cancer": (True, "bool", null, True),
    "NSCLC_stage": (("IB", "IIIB"), "tuple(str)", null, True),
    "anti_tumor_treatment_history": (False, "bool", null, True),
    "allergenic_EGFR_mutation_or_ALK_change": (False, "bool", null, Tru
e),
    "ECOG_score": ((0, 1), "tuple(int)", "points", True),
    "central_type_squamous_NSCLC_with_cavity_or_vessel_invasion": (True
, "bool", null, False),
    "interstitial_pneumonia_or_lung_disease_requiring_hormone_therapy":
 (True, "bool", null, False),
    "history_of_allogeneic_transplantation": (True, "bool", null, False
),
    "major_surgery_within_28_days": (True, "bool", null, False),
    "systemic_anti_cancer_treatment_prior_to_allocation": (True, "bool"
, null, False),
    "other_malignant_tumors_requiring_treatment_within_5_years": (True,
 "bool", null, False),
    "pregnant_or_lactating": (True, "bool", null, False)
}
```%

Future Steps



Challenges and Achievements

- Inconsistent pre-processing results
- Limited full-stack development, especially front end

- Learn and collaborated!
- Parameter tuning for LLM!



CURE CONNECT

FROM PATIENTS
TO ADVANCED THERAPEUTICS

Thank You!